Search Results

You are looking at 1 - 2 of 2 items for

  • Author: C Holmes x
Clear All Modify Search
Restricted access

M. Fearnley, A. Hodgkinson, A. L. Holmes and B. E. C. Nordin


Plasma oestrone and androstenedione levels have been measured in oophorectomized and sham-operated rats by means of radioimmunoassay. The mean oestrone level in the oophorectomized animals was approximately two-thirds of that in the intact animals while the androstendione levels were about half of those in the intact rats. A direct relationship was observed between the plasma oestrone and androstenedione levels in the control animals and to a lesser extent in the oophorectomized animals. The results indicate that approximately 50 % of circulating androstenedione and 30 % of circulating oestrone originate in the ovaries in the female adult rat.

Free access

SG Ashwell, JS Bevan, OM Edwards, MM Harris, C Holmes, MA Middleton and RA James

OBJECTIVE: Lanreotide Autogel is a sustained-release aqueous gel formulation supplied in a prefilled syringe, with injection volume <0.5 ml. The aim of this study was to establish the efficacy and safety of Autogel in patients with acromegaly previously treated with octreotide LAR. DESIGN: A 28-week, open, multicentre study. PATIENTS: Twelve patients with acromegaly, treated with 20 mg octreotide LAR for >4 months, with serum GH levels <10.0 mU/l. METHODS: Autogel (90 mg) was given every 28 days during weeks 0-12. At week 16 the dose was titrated based on GH levels at weeks 8 and 12. If GH levels were <2.0, 2.0-5.0, or >5.0 mU/l, Autogel was reduced to 60 mg, maintained at 90 mg, or increased to 120 mg respectively, for the next three injections. GH and IGF-I levels were reassessed at weeks 24 and 28. RESULTS: Ten patients completed the study. Five remained on 90 mg Autogel throughout the study; in two patients the dose was reduced to 60 mg from week 16; in three patients it was increased to 120 mg. Mean GH levels were: baseline, 3.0+/-1.7 mU/l; week 12, 3.5+/-1.8 mU/l; week 28, 3.3+/-1.6 mU/l (NS). Mean IGF-I levels were: baseline, 212+/-70 microg/l; week 12, 185+/-91 microg/l; week 28: 154+/-61 microg/l (P=0.027). Six patients at baseline and eight at week 28 had normalised GH and IGF-I levels. Three patients reported adverse events: musculoskeletal pain (n=2) and injection-site symptoms (n=1). CONCLUSIONS: Lanreotide Autogel is effective and well tolerated in patients with acromegaly. This study in a small group of patients with well-controlled acromegaly suggests that the majority of patients switched from 20 mg LAR to 90 mg Autogel will have equivalent or better disease control.